Epidermal growth factor receptor (EGFR) signaling has a critical role in oncogenic Kras-driven pancreatic carcinogenesis. However, the downstream targets of this signaling network are largely unknown. We developed a novel model system utilizing murine primary pancreatic ductal epithelial cells (PDECs), genetically engineered to allow time-specific expression of oncogenic Kras G12D from the endogenous promoter. We show that primary PDECs are susceptible to Kras G12D -driven transformation and form pancreatic ductal adenocarcinomas in vivo after Cdkn2a inactivation. In addition, we demonstrate that activation of Kras G12D induces an EGFR signaling loop to drive proliferation. Interestingly, pharmacological inhibition of EGFR fails to decrease Kras G12D -activated ERK or PI3K signaling. Instead our data provide novel evidence that EGFR signaling is needed to activate the oncogenic and pro-proliferative transcription factor c-MYC. EGFR and c-MYC have been shown to be essential for pancreatic carcinogenesis. Importantly, our data link both pathways and thereby explain the crucial role of EGFR for Kras G12D -driven carcinogenesis in the pancreas.
INTRODUCTION
Although novel chemotherapeutic regimens increased the overall survival of patients with advanced pancreatic ductal adenocarcinoma (PDAC), its prognosis remains dismal. The epidermal growth factor receptor (EGFR) signaling pathway has an outstanding role in the carcinogenesis of the disease. 1, 2 Despite being active in only a subgroup of patients, the EGFR inhibitor erlotinib is currently the only known targeted therapeutic for PDAC. EGFR belongs to a receptor tyrosine kinase family including ErbB2, ErbB3 and ErbB4. 3 Seven ligands, EGF, transforming growth factor α, betacellulin, heparin-binding EGF-like growth factor, amphiregulin, epiregulin and epigen can induce receptor dimerization and consecutive activation. 3 Effectors acting downstream of EGFR in the Kras G12D -induced circuit that drive tumor development in the pancreas remain incompletely understood.
In this study we generated a novel mouse model of PDAC, in which expression of the Kras G12D allele can be induced by a tamoxifen-inducible Cre recombinase in primary pancreatic ductal epithelial cells (PDECs). We provide evidence that Kras G12D -driven proliferation of PDECs depends on an EGFR signaling loop engaging the oncogenic transcription factor c-MYC (MYC afterwards).
RESULTS AND DISCUSSION
Mutations of the Kras oncogene are one of the earliest genetic events and have been shown to drive carcinogenesis in the pancreas. 4 To activate the expression of one allele of oncogenic Kras G12D from the endogenous gene promoter in PDECs, we isolated PDECs from R26
CreERT2
;LSL-Kras G12D/+ mice ( Figure 1a ). These cells show presence of ductal markers and the absence of acinar or endocrine markers (Supplementary Figure S1A) . PDECs express genes associated with a progenitor state (Supplementary Figure S1A) . Activation of the Cre recombinase in these cells by 4-hydroxytamoxifen (4-OHT) induced efficient recombination of the Kras locus ( Figure 1b) and 490% of the PDECs are recombined after 8 
days of 4-OHT treatment (Supplementary Figures S1B-D). Expression of oncogenic Kras
G12D induced GTPbound Ras to an extent observed in murine Kras G12D -driven PDAC cell lines (Figure 1c ). In addition, ERK becomes phosphorylated indicating activated canonical Kras signaling (Figures 1d and e) .
One road to PDAC originates in the pancreatic acinar cells likely via acinar-to-ductal metaplasia and pancreatic intraepithelial neoplasia (PanIN). 5 Although the contribution of ductal cells to the carcinogenesis in the pancreas is still a matter of debate, 6 available data suggest that ductal cells seem relatively refractory to Kras G12D -driven transformation. 7 Therefore, we investigated whether PDECs can form PDAC in vivo. We orthotopically transplanted ex vivo tamoxifen-treated PDECs from R26 CreERT2 ; LSL-Kras G12D/+ mice into the pancreas of immunodeficient mice. However, none of the transplanted mice (n = 3) developed PDAC in the investigated time period of 51 days. Furthermore, we detected no pre-malignant lesions in the pancreas of these mice (Supplementary Figure S2A) . In contrast, it has been reported that transplantation of PDECs, engineered to express Kras G12D , into C57Bl/6 mice, leads to the formation of ductal structures 1 resembling early PanIN lesions. 8 Considering low efficacy of Kras G12D -dependent tumor initiation, the number of orthotopically transplanted PDEC cells (1 × 10 6 versus 0.15 × 10 6 cells) might account for this discrepancy. Indeed, after increasing the number of transplanted PDECs to 7.5 × 10 5 cells, formation of PanIN-like structures (lineage label (YFP) and keratin 19 (K19) positive) was detected (Supplementary Figure S2B) . Besides activating mutations in the Kras gene, the tumor suppressor Cdkn2a is frequently lost in pre-neoplastic lesions. To model the human disease, we isolated PDECs from R26 CreERT2 ;LSL-Kras G12D/+ ;Cdkn2a lox/lox mice (Supplementary Figure S2C) . Tamoxifen treatment of these cells induced rapid loss of p16
Ink4a expression (Supplementary Figure  S2D) and canonical Kras G12D signaling is activated (Supplementary Figure S2E) . Orthotopic transplantation of Cdkn2a-deficient PDECs resulted in the development of invasive, proliferative, K19 positive and metastatic PDAC (Supplementary Figures S2F-H) . Thus, our model system suggests that PDECs contain a cellular population that is susceptible to Kras G12D -induced transformation. Expression of Kras G12D in PDECs induces proliferation (Figures 2a and b) accompanied by induction of cell cycle genes, like cyclin D1 or cyclin A (Figure 2c ). This is in agreement with observations that Kras G12D prevents premature senescence of PDECs 9 and induces a proliferative response. [9] [10] [11] [12] To identify pathways driving Kras G12D -induced proliferation, we used gene set enrichment analysis (GSEA) of mRNA expression profiles. Several of the gene sets significantly enriched in Kras G12D -expressing cells are linked to signatures controlled by the EGFR family (Figure 2d ; Supplementary Table S1 ). Accordingly, Kras G12D induced expression of the EGFR ligands amphiregulin and epiregulin (Figures 2d and e) , arguing for autocrine stimulation. Consistently, in murine PanIN organoids derived from ductal cells of Pdx1-Cre;LSL-Kras G12D/+ mice, 13 Kras G12D induced expression of EGFR ligands (Supplementary Figure S3) . Along with upregulation of EGFR ligands, increased receptor auto-phosphorylation was observed ( Figure 2f ). To test whether this EGFR phosphorylation is critical for mutant Kras-regulated proliferation we utilized the EGFR inhibitors erlotinib and gefitinib. Of note, in PDAC models, gefitinib has been demonstrated to be more specific for EGFR than erlotinib. 14 Both inhibitors diminished the Kras G12D -induced EGFR phosphorylation (Figure 2f ) and decreased expression of cell cycle regulators, like cyclin D1 (Figure 2g) . A link between the EGFR loop and cyclin D1 was recently described in Kras G12D -driven cancer formation in the pancreas in vivo.
1 Importantly, the Kras G12D -mediated inactivation of the Rb-dependent restriction point in the G1-phase of the cell cycle is controlled by EGFR (Figure 2g ).
EGFR signaling networks engage ERK-, PI3K-and STAT3-controlled pathways. Although expression of oncogenic Kras G12D -induced phosphorylation of ERK, AKT and its substrate GSK3β, both EGFR inhibitors did not distinctly change activation of these pathways (Figures 3a and b) . STAT3 phosphorylation was neither induced nor modulated by EGFR inhibitors (Figure 3c ). Involvement of EGFR in Ras induced transformation is context dependent 1, 2, 15 and the context appears to direct the signaling hubs engaged. Indeed, the hypomorphic waved-2 EGFR receptor variant reduced AKT activation but not ERK phosphorylation in primary keratinocytes of K5-SOS-F mice. 15 In the pancreas, the EGFR-controlled signaling hubs are incompletely understood. 16 Despite expression of the Kras G12V oncogene, most acinar cells express low EGFR levels and nuclear phospho-AKT or phospho-STAT3 staining is absent. 2 Inflammatory stimuli increase EGFR expression and induce AKT and STAT3 phosphorylation in acinar cells in the context of oncogenic Kras G12V , 2 arguing that AKT and STAT3 are part of the EGFR signaling network in this inflammatory CreERT2 ;LSL-Kras G12D/+ mice were treated with 4-OHT (200 nM) over time. pan-ERK and phospho-ERK were determined in western blots and quantified using the Odyssey Infrared Imaging System (Li-Cor Biosciences, Bad Homburg, Germany), assuring measurements in the linear range. Shown is the relative ERK phosphorylation of four independent experiments using four individual PDEC lines.
context. Furthermore, EGFR signaling increased the signaling output of the canonical Kras pathway to induce acinar-to-ductal metaplasia in Kras G12D -expressing acinar cells. 1 In established Krasdriven PDAC models, the EGFR is inconsistently linked to active ERK, AKT or STAT3.
1,2 Together, these observations clearly demonstrate that the EGFR signaling network is modulated by cell autonomous (for example, tumor suppressor status) and nonautonomous (for example, inflammatory environment) conditions.
The observation that ERK and AKT remain phosphorylated, despite an inactivation of EGFR auto-phosphorylation and cell cycle progression, suggests that different hubs sense the signal. To identify EGFR-engaged pathways, we again performed transcriptome profiling of EGFR inhibitor-treated PDECs. Enriched gene sets in Kras G12D -expressing PDECs with an active EGFR loop were linked to the cell cycle, DNA replication and repair as well as anabolic pathways (Supplementary Table 2 ). As we intended to identify an integration of the EGFR loop with the cell cycle machinery, we focused on transcription factors (TFT-MSigDB). We detected that the majority of EGFR-controlled gene sets were linked to the pro-proliferative E2F transcription factor family, corroborating the link of the EGFR loop to the cell cycle (Figure 3d ; Supplementary Table 3 ). In addition, we observed six signatures associated with transcription factors of the MYC family (Figures 3d and e; Supplementary Table 3 ). Performing a GSEA with curated gene sets (C2) of the MSigDB revealed 18 significant MYC gene sets linked to EGFR (Supplementary Table 4 ). MYC adopts a prominent role in Ras-driven cancers. [17] [18] [19] [20] [21] As MYC is strongly linked to the cell cycle of exocrine progenitors in the pancreas 22, 23 and to the E2F pathway in cell-based PDAC models, 24 we investigated the role of MYC. First, we quantified mRNA levels of MYC target genes upon treatment with EGFR inhibitors. Both inhibitors reduced the expression of the MYC target genes Ccna2, E2f1, eIf4e, Hspe1, Skp2, Ncl and Odc1 (Figure 3f ), indicating robust cross signaling between EGFR and MYC. Second, to demonstrate the regulation of these genes by MYC in the context of murine PDECs, we used a novel dualrecombinase system, allowing the time-specific manipulation of genes. 25 We isolated murine PDECs at PanIN stages (2-month-old mice) from Pdx1-Flp;FSF-Kras Oncogenic activity of MYC is regulated by phosphorylation of threonine 58 and serine 62 residues at the N-terminal MYC homology box I. 26, 27 Indeed, mutant Kras G12D activation induces N-terminal phosphorylation of MYC (Figure 4a ). Increased MYC phosphorylation was detected over time (Figures 4a and b) . Furthermore, Kras G12D induces MYC protein expression (Figure 4b ), which is accompanied by a slight induction of Myc mRNA (Figure 4c ). Both EGFR inhibitors prevent Kras G12D -induced MYC ;MYC lox/lox mice were isolated. In these cells expression of Kras G12D is induced in vivo and expression of floxed genes can be manipulated by the treatment of cells with 4-OHT. The cells were treated with 4-OHT (500 nM) for 24 h. The green fluorescent protein-expressing cells were fluorescence-activated cell sorting sorted as recently described. 50 Relative Myc, Ccna2, E2f1, Hspe1, Ncl and Odc1 mRNA expression levels were determined by qPCR using β-actin mRNA expression as reference and compared with untreated cells, in which expression was set to 1. The Pdx1-Flp, FSF-Kras G12D and the FSF-R26 CAG-Cre-ERT2 mouse lines were described recently in ref. 25 protein expression (Figure 4b ) and significantly reduce Myc mRNA expression (Figure 4c ). MYC regulation is controlled at multiple levels in PDAC. 21 How the EGFR loop is connected to MYC expression is currently unknown and awaits further investigations. Nevertheless, our results show that Kras G12D induces MYC expression, phosphorylation, and MYC target gene expression in an EGFR-dependent manner, suggesting that the Kras G12D -induced EGFR network is engaging MYC as an important effector.
Acinar cells cultured in suspension dedifferentiate and activate a ductal gene expression program. 5, 28 Therefore, the possibility exists that our PDEC preparations contain dedifferentiated acinar cells. However, in our hands, we were never able to serial passage and subculture acinar cells. This is in agreement with observations that ex vivo acinar cells lack the capacity to proliferate due to a p53-dependent growth arrest. 29 Since we subculture and serial passage the PDEC lines (only passage 3 to 8 were used for all experiments), a contamination with acinar cells is unlikely. To further address this point, lineage tracing technology using the ductal marker Hnf1b-Cre ER mouse line was used 30 (Figure 4d ). First, we activated Cre recombinase in a Hnf1b-Cre ER ;LSL-Kras G12D/+ ;
R26
Tom mouse by the intraperitoneal application of tamoxifen in vivo. 31 Two weeks after the last tamoxifen administration we isolated PDECs. Eighty-seven percent of these cells express the reporter gene tdTomato (Supplementary Figure S4A) , arguing for the ductal origin of the prepared cells. To further corroborate the EGFR-MYC loop in the Hnf1β-lineage, we isolated PDEC lines from untreated Hnf1b-Cre Figure S4B) . Even upon an increased 4-OHT dose, only 54% of the cells expressed tdTomato after 7 days (Supplementary Figure S4C) . However, the fraction of tdTomato expressing cells was increased to 91% after 15 days (Supplementary Figure S4D) . Then the Kras locus is recombined (Supplementary Figure S4E) and the canonical Ras-pathway is activated (Figure 4e ). In addition to ERK phosphorylation, the EGFR becomes phosphorylated, MYC protein and mRNA expression is induced and the G1-phase restriction point becomes inactivated upon the expression of Kras G12D (Figures 4e and f) . Both EGFR inhibitors prevent EGFR and Rb phosphorylation as well as MYC expression whereas ERK phosphorylation is not influenced (Figures 4e and f) . Together, the lack of proliferation of acinar cells ex vivo and our lineage tracing experiments argue that the described pathway and biology acts in the ductal lineage.
To further demonstrate the impact of the EGFR-dependent loop toward the proliferative capacity of Kras G12D expressing Hnf1b-Cre ER ;LSL-Kras G12D/+ ;R26 Tom PDECs, we measured growth of erlotinib-and gefitinib-treated cells. Both EGFR inhibitors reduce proliferation with a similar potency (Figure 4g) . To compare the effects of the EGFR blockade with the effects of a direct MYC inhibitor, we treated the cells with 10058-F4. This MYC inhibitor prevents the dimerization of MYC with MAX. 32 Similar to EGFR inhibitors, 10058-F4 reduces proliferation of Kras G12D -expressing PDECs, supporting an important function of MYC downstream of the EGFR.
Overall, PDECs are a valid model to gain mechanistic insights into Kras-driven processes in a specific pancreatic context. 6, [8] [9] [10] [11] [12] 33 In addition, PDECs are a tool for genetic screening experiments. A multipotent subpopulation of adult pancreatic ductal cells capable of reprogramming toward the endocrine lineage was recently described, arguing for a stem cell population in the ductal compartment. 35 Consistently, our observations demonstrate that PDECs express progenitor markers and are susceptible to Kras G12D -dependent transformation. In agreement, a non-islet Pdx1-positive PDEC subpopulation in the adult pancreas with a stem-like phenotype was described, harboring tumorigenic and metastatic capacity upon the expression of Kras G12D . 36, 37 In line with our data, MYC activation by Kras G12D was observed in this model and MYC was linked to the evolution of pancreatic cancer cells with stem cell-like features and metastatic potential. 36, 37 In addition, we analyzed recently published microarray datasets generated from duct and duct-like cells of Pdx1-Cre;LSL-Kras G12D/+ mice 38 at premalignant disease stages. Indeed, we observed Kras G12D -induced EGFR and MYC signatures using GSEA (Supplementary Figure S5) , suggesting that the molecular changes occurring in vivo are recapitulated by our in vitro model. Furthermore, our data show that an EGFR loop contributes to Kras G12D -driven proliferation of PDECs, well in line with recent data from Kras-dependent mouse models. 1, 2 In addition to this EGFR loop, a Kras G12D -activated autocrine loop engaging the insulin-like growth factor 1 receptor in Cdnk2a/ Trp53-double deficient PDECs has recently been described.
11
Whether EGFR-and insulin-like growth factor 1 receptordependent loops act in parallel to modulate signaling thresholds and whether the usage of such circuits is determined by tumor suppressive programs, awaits further analysis. However, in vivo findings indicate that the need of EGFR signaling to develop Kras G12D -driven PDACs is bypassed in a p53-deficient background, 1, 2 arguing that tumor suppressors determine the need of such loops.
In contrast to the requirement of EGFR for oncogenic Krasinduced pancreatic carcinogenesis, molecular hubs of the EGFR network are incompletely defined. Although the cooperation of Ras and MYC oncogenes to transform cells has been described in the past century 39 and many underlying molecular processes are known, 40 our data link for the first time two essential components of Kras-driven transformation in a pancreatic pre-neoplasia equivalent model. Like the EGFR loop, MYC essentially contributes to the carcinogenesis in the pancreas. [19] [20] [21] 41, 42 Especially, in embryonic stem cell-based genetically engineered mouse models the distinct effect of MYC silencing on disease progression and tumor formation was recently demonstrated. 19 MYC is highly expressed in multipotent pancreatic progenitor cells 43 and can autonomously drive tumor initiation and progression in the pancreas. 21, [44] [45] [46] The EGFR ligand transforming growth factor α dramatically accelerates MYC-driven carcinogenesis in the pancreas in vivo, 47 which is consistent with our observation of an EGFR-MYC cross signaling. Therefore, connecting EGFR to MYC underscores the importance of the EGFR network in the pancreatic carcinogenesis.
